Opinion|Videos|January 28, 2025
Leveraging Telehealth and Collaboration for Rural and Community Care Expansion
Author(s)Jeffrey V. Matous, MD
Jeffrey V. Matous, MD, discusses how primary barriers to the widespread use of bispecific antibody therapies in community practices can be addressed through innovative care models, while reflecting on key insights from ASH 2024 abstracts that could guide broader adoption of these therapies in community settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the primary barriers preventing widespread use of bispecific antibody therapies in community practices, and what innovative solutions or models of care could help address these challenges?
- Several ASH 2024 abstracts highlighted community center experiences with bispecific antibody therapies. What insights from these studies stand out to you, and how can they guide broader adoption of these therapies in the community setting?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Medicaid MFN Pricing Could Save $8.6 Billion
2
CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks
3
Active US Drug Shortages Rise for Third Straight Quarter
4
Access Barriers, Not Science, Slow Retina Care: Paul Hahn, MD
5